Loading data for ABCL — first visit, this takes a few seconds.
AbCellera Biologics Inc. (ABCL)
NasdaqGS: ABCL
· Real-Time Price · USD
11.94
+0.82 (7.37%)
At close: Aug 19, 2026, 5:25 PM
AbCellera Biologics Inc. (ABCL) Stock Price, Analysis & Data
7.37% (1D)
No data available
| Bid | 8.65 |
| Market Cap | 3.66B |
| Revenue (ttm) | 66.17M |
| Net Income (ttm) | -164.66M |
| Beta | 1.19 |
| EPS (ttm) | -0.54 |
| PE Ratio (ttm) | n/a |
| Forward PE | -16.7 |
| P/B (ttm) | 4.08 |
| P/S (ttm) | 55.31 |
| Earnings Date | Nov 5, 2026 |
| Ask | 14.79 |
| Volume | 7,592,271 |
| Avg. Volume (20D) | 8,141,037 |
| Open | 11.54 |
| Previous Close | 11.12 |
| Day's Range | 11.47 - 12.02 |
| 52-Week Range | 2.75 - 12.02 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ABCL
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, su...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 11, 2020
Employees 562
Stock Exchange NasdaqGS
Ticker Symbol ABCL
Website https://www.abcellera.com
Financial Performance
In 2025, AbCellera Biologics's revenue was 75.13M, an increase of 160.56% compared to the previous year's 28.83M. Earnings were -146.41M, a decrease of -10.1%.
Financial StatementsEarnings Surprise
AbCellera Biologics has released their quarterly earnings on Aug 5, 2026:
AbCellera Biologics Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2